ExOne Showcases Ability to 3D Print Virtually Any Powder Material in New Corporate Video, “Let’s Make it Right”
20.10.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that it is open to developing virtually any powder material in partnership with manufacturers for their specific application.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005203/en/
The ExOne Company has released a new corporate video, "Let's Make it Right," showcasing the ability of its sustainable binder jetting technology to 3D print virtually any type of powder. ExOne has already qualified more than 20 metals, ceramics and composites for 3D printing, but is now developing materials such as pulverized concrete and other waste products with customers. (Photo: Business Wire)
The material flexibility and sustainability of ExOne’s patented binder jet 3D printing technology is showcased in a new corporate video unveiled today, “Let’s Make it Right.” The video is a celebration of ExOne’s employees and their accomplishments over more than 20 years as the company prepares to be acquired by Desktop Metal.
Beginning in the mid-1990s, ExOne pioneered the commercial development of MIT’s patented binder jet 3D printing process, which transforms powdered materials into precision parts or tooling at high speeds. An industrial printhead selectively deposits binder into a bed of powder particles creating a solid part one layer at a time, just like printing on sheets of paper.
The company’s RTS-300, launched in 1998, was the first commercially available metal binder jet system. ExOne later began binder jetting sand for metalcasting molds and cores. Today, ExOne has a portfolio of eight sand and metal 3D printing systems that can print a wide range of powders into highly dense parts, or even parts with controlled porosity, for specific applications.
“Binder jet 3D printing is one of the few additive manufacturing technologies that holds the promise of being an all-purpose manufacturing tool; it can print just about any powdered material into any form or functional purpose. In recent years, advancements in machine design and binder chemistries have helped us take a leap closer to that ultimate goal,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We are thankful to all of our former and current employees, as well as our R&D partners around the world, who have helped us advance binder jetting to where it is today and continue to support development efforts around this important green technology.”
Unique Material Flexibility in 3D Printing
Binder jetting is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as broad material flexibility, which is just beginning to be untapped because of ExOne’s improvements in machine design and binder chemistries.
To achieve high-density parts, such as metals, the printed part is typically sintered in a furnace to fuse the particles together into a high-density solid object. Porous parts, often created with sand or other large-particle media, can also be infiltrated with resins or metals to achieve desired properties and create unique composites.
Two new case studies illustrate the broad range of ExOne’s binder jetting technology beyond traditional industrial applications:
- Luxury sound system company, Deeptime, manufactures its speakers with 3D printed sand that is infiltrated with a proprietary solution to deliver material properties that are 86% more rigid than MDF, leading to double the sound damping compared to traditional speakers and much higher performance.
- Carnegie Mellon University’s School of Architecture, meanwhile, is developing binder jetting of pulverized concrete and other recycled materials that are then infiltrated with resins for use as durable outdoor architectural pieces. This approach represents the future of cradle-to-grave, ecologically intelligent building design.
ExOne’s resin-infiltrated sand 3D printing for architectural restoration was a finalist in the 2021 Awards for Composites Excellence at CAMX, the Composites and Advanced Materials Expo.
Full Flexibility of Binder Jet 3D Printing
Among the broad categories of materials that ExOne can now develop to manufacturer specifications:
- Aluminum alloys
- Carbides
- Copper and copper alloys
- Nickel alloys
- Nitrides
- Oxides
- Precious metal alloys, including silver and gold
- Refractory metals, such as tungsten and molybdenum alloys
- Sands
- Stainless steels, such as 17-4PH, 316L and 304L
- Titanium alloys, such as Ti64
- Tool steels, such as M2 and H13
- Waste products such as concrete and more
ExOne’s new corporate video is available at www.exone.com/MakeitRight.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005203/en/
Contact information
Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
